Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature 395, 13-15 (3 September 1998) | doi:10.1038/25595
Open Innovation Challenges
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
nature jobs
Postdoctoral Fellow - Computational Genomics - Team 78 – Ref: 80464
- Wellcome Trust Sanger Institute
- Hinxton, Cambridgeshire CB10 1, UK
Gastroenterologist
- South Atlanta Medical Clinic, PC (GI Group)
- Atlanta, GA, USA
Cancer: Has the smart bomb been defused?
Steven P. Linke1
A goal of cancer research is to develop therapies that can selectively kill tumour cells without adversely affecting normal cells — this is crucial for both the short-term comfort and long-term survival of patients. One such agent is a genetically engineered adenovirus from ONYX Pharmaceuticals, called ONYX-015, which is thought to selectively replicate in (and kill) tumour cells deficient for the p53 tumour-suppressor pathway, having little toxicity to normal cells1,2.
- Steven P. Linke is at the Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, 9,000 Rockville Pike, Bethesda, Maryland 20892-4255, USA.
e-mail: Email: slinke@helix.nih.gov
To read this story in full you will need to login or make a payment (see right).

